Welcome to our dedicated page for Oculis Holding news (Ticker: OCS), a resource for investors and traders seeking the latest updates and insights on Oculis Holding stock.
Oculis Holding AG (OCS) is a clinical-stage biopharmaceutical company pioneering novel treatments for sight-threatening eye diseases. This news hub provides investors and healthcare professionals with timely updates on OCS's therapeutic advancements in ophthalmology.
Access official press releases and curated analysis covering clinical trial developments, regulatory milestones, and strategic partnerships. Our repository includes updates on key pipeline assets like OCS-01 for diabetic macular edema and OCS-02 for dry eye disease, along with neuro-ophthalmology innovations.
Stay informed about critical events including Phase trial results, FDA communications, licensing agreements, and scientific conference presentations. All content is verified through primary sources to ensure accuracy in this complex regulatory landscape.
Bookmark this page for streamlined tracking of Oculis's progress in developing precision therapies for retinal disorders and ocular surface diseases. Check regularly for material updates that could impact understanding of the company's clinical and commercial potential.
Oculis Holding AG (Nasdaq: OCS) has announced an update to its share capital structure. The company has issued 589,974 new registered ordinary shares with a nominal value of CHF 0.01 each. This issuance consists of:
- 310,941 shares issued for equity awards under the Company's Stock Option and Incentive Plan
- 279,033 shares issued through EBAC warrant exercises
Following these issuances, which occurred between January 1, 2024, and December 31, 2024, Oculis's total registered shares have increased to 54,533,674. The change has been officially registered with the Zug Commercial Register.
Oculis Holding AG (Nasdaq: OCS) and EURETINA have announced the 2025 Ramin Tadayoni Award, continuing their collaboration to honor the legacy of Professor Tadayoni, who passed away on April 19, 2024. The award, worth €30,000 for research support plus €5,000 for the candidate, aims to support exceptional postgraduate scholars in retina research.
Applications will be accepted until May 12, 2025, with the winner to be announced at the EURETINA Congress in Paris (September 4-7, 2025). Dr. Andrea Govetto was named the inaugural recipient in 2024 for his work on developing a computational model of fluid flow and retinal tissue deformation in macular edema.
Professor Tadayoni served as Oculis' Chief Scientific Officer and was a distinguished figure in ophthalmology, having authored over 320 medical articles and received numerous prestigious awards including the Jules Gonin Award.
Oculis (OCS) is hosting an R&D Event to showcase progress on its three pipeline assets. Key highlights include:
- Updates on DIAMOND and EMERALD Phase 3 trials for DME with >800 enrolled patients and topline data expected in Q2 2026
- Development plans for Licaminlimab (OCS-02) in dry eye disease with Phase 2/3 study starting in H2 2025
- New data from ACUITY Phase 2 trial for Privosegtor (OCS-05) in acute optic neuritis
The company also announced expansion of Privosegtor development into non-arteritic anterior ischemic optic neuropathy (NAION) and multiple sclerosis relapses. A follow-up investor meeting is scheduled in Iceland on April 29, 2025.
Oculis (Nasdaq: OCS) has completed enrollment for its Phase 3 DIAMOND trials evaluating OCS-01 eye drops in diabetic macular edema (DME). The program consists of two double-masked, randomized, multi-center trials with over 800 patients across 119 sites globally.
The DIAMOND (DIAbetic Macular edema patients ON a Drop) program represents the first-ever pivotal trial for a topical DME treatment. Topline data is expected in Q2 2026, followed by an NDA submission. If approved, OCS-01 would become the first topical eye drop treatment for DME, addressing unmet needs for early intervention and patients with inadequate anti-VEGF therapy response.
Oculis announced the vesting and settlement of previously granted Restricted Stock Units (RSUs) for company directors. The notification specifically pertains to transactions by Persons Discharging Managerial Responsibilities, with particular reference to director Riad Sherif's RSU vesting in April 2025.
Oculis Holding AG (Nasdaq: OCS) announces an upcoming R&D Day scheduled for April 15, 2025, from 10:00 AM to 12:00 PM ET at the Intercontinental New York Barclay hotel. The event, available both in-person and virtually, will showcase updates on the company's late-stage clinical candidates and development strategy.
The presentation will feature prominent Key Opinion Leaders (KOLs) specializing in retina, inflammation, precision medicine, and neuro-ophthalmology from prestigious institutions including USC, University of Nevada, UC Irvine, University of Bern, University of Miami, Mount Sinai, McGill University, and Stanford University.
Key topics include:
- Updates on Phase 3 DIAMOND trials of OCS-01 eye drops for diabetic macular edema (DME)
- Licaminlimab (OCS-02) development plans for dry eye disease (DED)
- Expanded analysis of ACUITY Phase 2 trial
- Development plans for Privosegtor (OCS-05) in acute optic neuritis
Oculis has disclosed multiple notifications regarding transactions executed by a Person Discharging Managerial Responsibilities (PDMR) under a pre-planned 10b5-1 trading plan. The sales transactions were conducted by R. Sherif over five consecutive days from March 14-20, 2025, in compliance with Rule 10b5-1(c)(1) of the Securities Exchange Act of 1934.
Oculis has disclosed insider trading notifications related to equity transactions by company executives and board members. The transactions include annual equity incentive awards granted to executive committee members and a share purchase by a board director. Riad Sherif received RSUs, while Sylvia Cheung and Pall Ragnar Johannesson were granted options. Additionally, board member Lionel Carnot purchased ordinary shares of the company.
Oculis (Nasdaq: OCS) reported its Q4 and full year 2024 financial results, highlighting significant clinical advancements across its pipeline. The company completed an oversubscribed $100 million equity financing and reported cash position of $109 million as of December 31, 2024, providing runway into early 2028.
Key clinical developments include positive topline results from the ACUITY Phase 2 trial of Privosegtor (OCS-05) in acute optic neuritis and the RELIEF trial of Licaminlimab (OCS-02) in dry eye disease. The company is on track to complete enrollment for Phase 3 DIAMOND trials of OCS-01 in diabetic macular edema.
Financial highlights:
- Q4 2024 net loss: $32.6 million vs $14.1 million in Q4 2023
- FY2024 net loss: $97.4 million vs $98.8 million in 2023
- R&D expenses increased to $59.1 million in 2024 from $32.6 million in 2023
- G&A expenses rose to $24.8 million in 2024 from $19.5 million in 2023
Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC), a global biopharmaceutical company focused on eye care and sight preservation, has announced its participation in the upcoming Leerink Global Healthcare Conference.
The company's Chief Financial Officer, Sylvia Cheung, will present on March 11, 2025, at 3:00pm ET in Miami Beach, FL. Investors can request one-on-one meetings through their institutional representatives.
A live webcast of the fireside chat will be accessible through the Events and Presentations section of the Oculis website under Investors & Media.
